Clinical Trials in Myositis: Where Do We Stand?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F21%3AN0000017" target="_blank" >RIV/00023728:_____/21:N0000017 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/21:10429239
Result on the web
<a href="https://doi.org/10.1007/s40674-021-00180-3" target="_blank" >https://doi.org/10.1007/s40674-021-00180-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s40674-021-00180-3" target="_blank" >10.1007/s40674-021-00180-3</a>

Result language
angličtina
Original language name
Clinical Trials in Myositis: Where Do We Stand?
Original language description
Purpose of review There are currently no universally accepted management guidelines for idiopathic inflammatory myopathies (IIM), with only limited clinical evidence available to guide treatment decisions. However, the situation is changing and the number of clinical trials is growing, thanks to the improvement in our understanding of disease pathogenesis and availability of novel immunomodulatory drugs. We provide an overview of completed and ongoing interventional clinical trials evaluating the efficacy of pharmacotherapy in various forms of adult IIMs. Recent findings Unfortunately, the results of many trials are not very encouraging and no single drug seems to be a real breakthrough, reflecting the difficulty associated with studying such rare and heterogenous group of diseases. Several drugs have proven good efficacy in certain IIM subgroups and there are promising novel candidates raising hope for the future. The efficacy of intravenous immunoglobulins in dermatomyositis has been clearly confirmed. Encouraging reports, albeit very preliminary, are coming from trials with JAK inhibitors. We eagerly await the results of a large clinical trial with abatacept or the cannabinoid receptor modulator lenabasum.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)